Cantor Fitzgerald Starts Coverage of Milestone Pharmaceuticals with Overweight Rating and $3 Target

Cantor Fitzgerald initiates Overweight coverage on Milestone, citing Cardamyst’s strong PSVT launch potential and $250-300M peak sales outlook.